Abstract

Introduction
COVID-19 is a fast-spreading and alarming global public health issue1. Evans’ syndrome, in contrast, is a rare condition which is characterised by autoimmune disorders, such as autoimmune haemolytic anaemia (AIHA) and immune thrombocytopenia and/or immune neutropenia, which occur simultaneously or consecutively2.
The recommended first-line treatment for Evans’ syndrome is corticosteroids, but these are potentially harmful in patients with COVID-19. On the other hand, intravenous immunoglobulins and other non-immunosuppressive treatments are not adequately successful treatment options in AIHA. In this article, we describe how we treated a case of COVID-19 in a patient who presented with Evans Syndrome.

Downloads

Authors

Nazlim Aktug Demir - Department of Infectious Diseases and Clinical Microbiology

Abdulkadir Basturk - Department of Haematology

Onur Ural - Department of Infectious Diseases and Clinical Microbiology

Sua Sumer - Department of Infectious Diseases and Clinical Microbiology

Batuhan Erdogdu - Department of Haematology

Hatice E. Kiratli - Department of Infectious Diseases and Clinical Microbiology

Jale B. Celik - Department of Anaesthesiology

Mustafa Koplay - Department of Radiology

Husamettin Vatansev - Department of Biochemistry, Selcuk University, Faculty of Medicine, Konya, Turkey

  • Abstract viewed - 10 times
  • PDF downloaded - 3 times